JPH09309841A - Preparation for external use for skin - Google Patents
Preparation for external use for skinInfo
- Publication number
- JPH09309841A JPH09309841A JP8148699A JP14869996A JPH09309841A JP H09309841 A JPH09309841 A JP H09309841A JP 8148699 A JP8148699 A JP 8148699A JP 14869996 A JP14869996 A JP 14869996A JP H09309841 A JPH09309841 A JP H09309841A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- preparation
- methanol
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 47
- 241001598107 Imperata Species 0.000 claims abstract 6
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 230000003712 anti-aging effect Effects 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 23
- 239000008346 aqueous phase Substances 0.000 abstract description 14
- 238000003756 stirring Methods 0.000 abstract description 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract description 11
- 230000006872 improvement Effects 0.000 abstract description 10
- 239000002304 perfume Substances 0.000 abstract description 10
- 238000010438 heat treatment Methods 0.000 abstract description 9
- 239000000843 powder Substances 0.000 abstract description 9
- 239000008213 purified water Substances 0.000 abstract description 7
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 239000004166 Lanolin Substances 0.000 abstract description 4
- 235000021355 Stearic acid Nutrition 0.000 abstract description 4
- 235000013871 bee wax Nutrition 0.000 abstract description 4
- 239000012166 beeswax Substances 0.000 abstract description 4
- 235000019388 lanolin Nutrition 0.000 abstract description 4
- 229940039717 lanolin Drugs 0.000 abstract description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract description 4
- 230000003449 preventive effect Effects 0.000 abstract description 4
- 239000008117 stearic acid Substances 0.000 abstract description 4
- 230000004792 oxidative damage Effects 0.000 abstract description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000008020 evaporation Effects 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 238000007788 roughening Methods 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 63
- 239000012071 phase Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 239000000203 mixture Substances 0.000 description 30
- 239000000047 product Substances 0.000 description 21
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000000401 methanolic extract Substances 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000037303 wrinkles Effects 0.000 description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- -1 methanol and ethanol Chemical class 0.000 description 11
- 102000035195 Peptidases Human genes 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000004365 Protease Substances 0.000 description 7
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 7
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 7
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 7
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 102000001938 Plasminogen Activators Human genes 0.000 description 6
- 108010001014 Plasminogen Activators Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 229940127126 plasminogen activator Drugs 0.000 description 6
- 230000009759 skin aging Effects 0.000 description 6
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000036570 collagen biosynthesis Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000218691 Cupressaceae Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 238000006388 chemical passivation reaction Methods 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229940055577 oleyl alcohol Drugs 0.000 description 3
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 3
- 235000011118 potassium hydroxide Nutrition 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 229960000401 tranexamic acid Drugs 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 2
- 235000003097 Artemisia absinthium Nutrition 0.000 description 2
- 240000001851 Artemisia dracunculus Species 0.000 description 2
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 241000234653 Cyperus Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 240000007171 Imperata cylindrica Species 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001138 artemisia absinthium Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 230000037393 skin firmness Effects 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 1
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
- XGWIJUOSCAQSSV-XHDPSFHLSA-N (S,S)-hexythiazox Chemical compound S([C@H]([C@@H]1C)C=2C=CC(Cl)=CC=2)C(=O)N1C(=O)NC1CCCCC1 XGWIJUOSCAQSSV-XHDPSFHLSA-N 0.000 description 1
- GFVYDNHWTCHDSN-UHFFFAOYSA-N 14-methylpentadecyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C GFVYDNHWTCHDSN-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000206609 Porphyra Species 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 244000128206 Pyracantha coccinea Species 0.000 description 1
- 235000003105 Pyracantha coccinea Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 206010039740 Screaming Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 241000985245 Spodoptera litura Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 244000059271 Zingiber aromaticum Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- QKHBMQWPOUUMQZ-BDQAORGHSA-M sodium;hydron;(2s)-2-(octadecanoylamino)pentanedioate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC([O-])=O QKHBMQWPOUUMQZ-BDQAORGHSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Landscapes
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は肌用外用剤に関し、
特に化粧料(医薬部外品を含む。以下同じ。)等に配合
して優れた老化防止作用を奏すると共に、接触性皮膚
炎、乾癬等の種々の皮膚疾患による肌荒れ症状の他、健
常人の肌荒れ、荒れ性に対して改善・予防作用を有し、
かつ皮膚の脂質成分の酸化防止や皮膚の酸化傷害等に有
効な抗酸化作用をも発揮する肌用外用剤に関する。TECHNICAL FIELD The present invention relates to an external preparation for skin,
In particular, when combined with cosmetics (including quasi-drugs. The same applies hereinafter), it has an excellent anti-aging effect, and it also causes rough skin symptoms due to various skin diseases such as contact dermatitis and psoriasis, as well as that of healthy people. It has an improving / preventive action against rough skin and rough skin,
In addition, the present invention relates to an external preparation for skin that also exhibits an antioxidant effect that is effective in preventing the oxidation of lipid components of the skin and oxidative damage to the skin.
【0002】[0002]
【従来の技術および発明が解決しようとする課題】老化
は全身の臓器で進行しているが、その中でも目で見るこ
とができる皮膚、とりわけ特に意識が集中しやすい顔面
については、シワ・小ジワ・ソバカス、タルミの発生、
ハリ・ツヤの消失といった容貌上の変化が、世の多くの
中高年齢者、とりわけ女性を悩ませている。これまでに
も、老化防止用外用剤の必要性が叫ばれてきていたが、
老化に関するメカニズム、定義などで明らかではない部
分が多かったため、従来の化粧料では、ムコ多等類やコ
ラーゲンなどの生化学製品および合成高分子製品を配合
して水分保持に務めるという方法を選択してきたにすぎ
ない。しかしそれだけでは、皮膚の老化を充分に防止す
ることができないことも明らかとなってきた。2. Description of the Related Art Aging is progressing in organs of the whole body, and among them, the visible skin, especially the face on which the consciousness is particularly concentrated, is wrinkled or wrinkled.・ The occurrence of freckles and tarmi,
Physical changes such as the loss of firmness and gloss have plagued many middle-aged people in the world, especially women. Up until now, the need for an external anti-aging agent has been screaming,
Since there are many unclear points in the mechanism and definition of aging, in conventional cosmetics, we have selected the method of blending biochemical products such as mucokind and collagen and synthetic polymer products to help retain water. It ’s just However, it has become clear that this alone cannot sufficiently prevent skin aging.
【0003】ところが近年、老化に関する研究が進めら
れ、皮膚老化の原因としてマクロ的に見れば加齢が重要
な因子であり、さらに乾燥、酸化、太陽光(紫外線)等
も皮膚老化に関わる直接的な因子として挙げられてきて
いる。それら因子の中でも太陽光(紫外線)は、光老化
と呼ばれる変化において重要な役割を果たしていること
が明らかとなってきた。上に記した顔面は、全身で最も
光老化が進行しやすい部位であるが、光老化した皮膚で
は真皮の最も主要なマトリックス成分であるコラーゲン
線維が著明に減少していることも明らかとなってきた。
そしてシワ・小ジワの発生、ハリの消失といった現象が
コラーゲン線維の減少と密接に関係していることも示唆
されてきている。このように、皮膚老化に関しては、様
々な皮膚老化因子、中でも太陽光(紫外線)曝露に伴
い、真皮における主要な細胞である線維芽細胞の増殖活
性やコラーゲン等の合成機能が低下して、このコラーゲ
ン等のターンオーバー速度も遅くなる。その結果とし
て、皮膚の弾力がなくなり、しわやたるみも増加して、
皮膚の老化が進行する。However, in recent years, research on aging has been advanced, and aging is an important factor as a cause of skin aging from a macroscopic viewpoint, and dryness, oxidation, sunlight (ultraviolet rays), etc. are also directly involved in skin aging. Has been listed as a factor. Among these factors, it has become clear that sunlight (ultraviolet ray) plays an important role in a change called photoaging. The face described above is the site where photoaging is most likely to progress in the whole body, but it is also clear that collagen fibers, which are the main matrix components of the dermis, are significantly reduced in photoaged skin. Came.
It has also been suggested that phenomena such as the generation of wrinkles and fine wrinkles and the disappearance of firmness are closely related to the decrease of collagen fibers. As described above, with respect to skin aging, various skin aging factors, in particular, exposure to sunlight (ultraviolet rays) causes a decrease in the proliferative activity of fibroblasts, which are the main cells in the dermis, and the synthetic function of collagen and the like. The turnover speed of collagen etc. also becomes slower. As a result, the skin loses elasticity, wrinkles and sagging increase,
Skin aging progresses.
【0004】一方、肌のトラブルの別の要因として種々
の皮膚疾患や肌荒れがある。これらに対して改善・予防
効果を有する治療薬、皮膚外用剤、化粧料等の有効成分
としては、従来より抗炎症作用を有する、あるいは保湿
効果の高いアミノ酸や多糖、脂質、抽出エキス等が、そ
の使用効果が特徴的であるために用いられてきた。しか
し近年の研究により、種々の皮膚疾患の病像形成にはプ
ロテアーゼが関与していることが明らかにされつつあ
る。例えば炎症性異常角化性疾患の代表である乾癬で
は、その患部表皮において高いプラスミノーゲンアクチ
ベーター(Plasminiogen activator:PA)活性が認め
られている。PAはセリンプロテアーゼの1つである
が、Hausteinは、乾癬表皮の特に錯角化部位に強いPA
活性が存在することを報告し(Arch.Klin.Exp.Dermato
l;234,1969)、FrakiとHopsu-Havuは、乾癬鱗屑から高
濃度の塩溶液を用いてPA活性を抽出した(Arch.Derma
tol.Res;256,1976)。また、尋常性天疱瘡においては表
皮細胞内で多量に合成されたPAが、細胞外に存在する
PlasminiogenをPlasminに転換し、これが細胞間結合物
質を消化することにより細胞間に組織液が貯留して表皮
内水泡が形成されることが、in vitroの実験系において
明らかにされている(Morioka S.et al:J.Invest.Derma
tol;76,1981)。またプロテアーゼは、角質層形成など
表皮の正常な角化過程においても重要な役割を果たして
いると考えられており(Ogawa H.,Yoshiike T.:Int.J.D
ermatol;23,1984)、肌改善あるいは皮膚疾患の治療薬
として、プロテアーゼ阻害剤を用いる試みがなされるよ
うになってきている。On the other hand, there are various skin diseases and rough skin as another factor of skin troubles. As an active ingredient for therapeutic agents, skin external preparations, cosmetics, etc. that have an improving / preventive effect against these, amino acids and polysaccharides, lipids, extracted extracts, etc., which have anti-inflammatory effects or have a high moisturizing effect than before, It has been used because of its characteristic use effect. However, recent studies have revealed that proteases are involved in the pathogenesis of various skin diseases. For example, in psoriasis, which is a representative of inflammatory dyskeratosis, high plasminogen activator (PA) activity is observed in the affected epidermis. PA is one of the serine proteases, but Haustein has strong PA in the epidermis of psoriasis
Report the existence of activity (Arch.Klin.Exp.Dermato
L; 234,1969), Fraki and Hopsu-Havu extracted PA activity from psoriatic scales using a highly concentrated salt solution (Arch. Derma).
tol.Res; 256,1976). Also, in pemphigus vulgaris, PA synthesized in epidermal cells in a large amount exists extracellularly.
It has been revealed in an in vitro experimental system that Plasminiogen is converted to Plasmin, which digests intercellular binding substances to store interstitial fluid between cells and form blisters in the epidermis (Morioka S. et al: J.Invest.Derma
tol; 76,1981). Proteases are also considered to play an important role in the normal keratinization process of the epidermis such as stratum corneum formation (Ogawa H., Yoshiike T .: Int. JD.
ermatol; 23, 1984), attempts have been made to use protease inhibitors as agents for improving skin or treating skin diseases.
【0005】[0005]
【課題を解決するための手段】以上のような現況に鑑
み、本発明者は鋭意検討を重ねた結果、チガヤの抽出物
が、皮膚内の線維芽細胞に働きかけることにより、真皮
の重要な成分の一つであるコラーゲン生合成を促進させ
る作用を有すると共に、トリプシン型セリンプロテアー
ゼの阻害活性を有し、増殖性の皮膚肥厚、紅斑、乾燥、
落屑を伴う肌荒れを極めて有効に改善することを見出し
た。またさらに該抽出物が、ビタミンEと同程度または
それ以上の抗酸化力があることを見出した。本発明者ら
は上記知見に基づいて本発明を完成するに至った。[Means for Solving the Problems] In view of the present situation as described above, the present inventor has conducted diligent studies, and as a result, the extract of Chigaya has an important component of the dermis by acting on fibroblasts in the skin. It has the action of promoting collagen biosynthesis, which is one of the following, and also has the inhibitory activity of trypsin type serine protease, proliferative skin thickening, erythema, dryness,
It was found that skin roughness accompanied by desquamation is extremely effectively improved. Furthermore, it has been found that the extract has an antioxidant power equal to or higher than that of vitamin E. The present inventors have completed the present invention based on the above findings.
【0006】すなわち本発明は、チガヤ(学名:Impera
ta cylindrica)の抽出物を配合することを特徴とする
肌用外用剤である。ここで肌用外用剤とは、頭髪、頭皮
等を除く人体等の皮膚表面に適用するものをいう。さら
に、本発明によれば、チガヤ(学名:Imperata cylindr
ica)の抽出物を有効成分とする老化防止剤、肌荒れ改
善剤および抗酸化剤が提供される。That is, the present invention refers to Chigaya (scientific name: Impera
ta cylindrica) is an external preparation for skin characterized by being blended with an extract. Here, the external preparation for skin refers to an agent applied to the skin surface of the human body and the like excluding hair and scalp. Furthermore, according to the present invention, Chigaya (scientific name: Imperata cylindr
The present invention provides an anti-aging agent, a rough skin improving agent, and an antioxidant, which contain an extract of ica) as an active ingredient.
【0007】以下に、本発明の構成について詳述する。
本発明に用いられるチガヤ(学名:Imperata cylindric
a)は、北海道から九州およびアジア、アフリカに分布
し、原野、河原、草地、道ばたなどに群がって叢生する
多年草でイネ科チガヤ属に属する草である。本発明に用
いられる抽出物は、上記根茎を抽出溶媒と共に浸漬また
は加熱環流した後、濾過し、濃縮して得られる。また本
発明に用いられる抽出溶媒は、通常抽出に用いられる溶
媒であれば何でもよく、特にメタノール、エタノール等
のアルコール類、含水アルコール、アセトン、酢酸エチ
ルエステル等の有機溶媒を単独あるいは組み合わせて用
いることができる。チガヤは、養毛・育毛剤の一成分と
しては知られているが(特開平4−193819号公
報)、肌用の外用剤には未だ適用されていなかったもの
である。The structure of the present invention will be described in detail below.
Chigaya used in the present invention (scientific name: Imperata cylindric
a) is a perennial herb that is distributed from Hokkaido to Kyushu, Asia, and Africa, and grows in fields, rivers, grasslands, roadsides, etc. The extract used in the present invention can be obtained by immersing or heating the above rhizome with an extraction solvent or refluxing, filtering and concentrating. Further, the extraction solvent used in the present invention may be any solvent that is usually used for extraction, and particularly alcohols such as methanol and ethanol, hydrous alcohols, acetone, and organic solvents such as acetic acid ethyl ester may be used alone or in combination. You can Chigaya is known as one component of a hair-growth / hair-growth agent (Japanese Patent Laid-Open No. 193819/1992), but it has not yet been applied as an external preparation for the skin.
【0008】本発明におけるチガヤ抽出物の配合量は、
老化防止剤あるいは肌荒れ改善剤として用いる場合、外
用剤全量中乾燥物として、0.005〜20.0重量
%、好ましくは0.01〜10.0重量%である。0.
005重量%未満であると十分な老化防止効果、肌荒れ
改善・予防効果が発揮されず、20.0重量%を超える
と製剤化が難しいので好ましくない。また、10.0重
量%以上配合してもさほど大きな効果の向上は見られな
い。また、チガヤ抽出物を抗酸化剤として用いる場合に
は、添加量は一般に0.00001〜5.0重量%(乾
燥物として)であり、好ましくは0.00005〜2.
0重量%の量を添加することにより、安全で優れた抗酸
化作用が発揮される。[0008] The blending amount of the cypress extract in the present invention is
When it is used as an anti-aging agent or a rough skin improving agent, it is 0.005 to 20.0% by weight, preferably 0.01 to 10.0% by weight, as a dry product in the total amount of the external preparation. 0.
If it is less than 005% by weight, sufficient antiaging effect and rough skin improving / preventing effect are not exhibited, and if it exceeds 20.0% by weight, formulation is difficult, which is not preferable. Further, even if it is blended in an amount of 10.0% by weight or more, the effect is not so much improved. Further, when the extract of Chigaya is used as an antioxidant, the amount added is generally 0.00001 to 5.0% by weight (as a dried product), preferably 0.00005 to 2.
By adding 0% by weight, safe and excellent antioxidant action is exhibited.
【0009】チガヤ抽出物を配合する対象物としては化
粧料が好ましく、抗酸化作用や、肌荒れ改善作用、ある
いは抗老化作用の必要な各種化粧品、例えばクリーム、
ローション、乳液、ヘアオイル、シャンプー、リンス、
石鹸等に添加すると優れた効果を発揮する。Cosmetics are preferable as an object to be blended with the extract of Chigaya, and various cosmetics, such as creams, which require antioxidant action, rough skin improving action, or anti-aging action.
Lotion, emulsion, hair oil, shampoo, conditioner,
When added to soap, etc., it exhibits excellent effects.
【0010】さらに、本発明の肌用外用剤は、プロテア
ーゼ阻害剤としての応用も可能である。プロテアーゼ阻
害剤のプロテアーゼとは、ペプチド結合の加水分解を触
媒する酵素の総称であり、このプロテアーゼはペプチダ
ーゼおよびプロテイナーゼに分類される。前者はペプチ
ド鎖のアミノ基末端やカルボキシル基末端の外側より、
ペプチド結合を切り離していく酵素で、後者はペプチド
鎖内部の特定の結合を切断する酵素である。後者プロテ
イナーゼは、その活性触媒基の種類により、さらにセリ
ン系、システイン系、アスパラギン酸系、金属系の4つ
に大別され、それぞれに特異的な阻害剤が存在してい
る。本発明におけるプロテアーゼ阻害剤とは、このうち
の特にセリンプロテアーゼに対して阻害活性を示すこと
を特徴としている。Further, the external preparation for skin of the present invention can be applied as a protease inhibitor. Protease, which is a protease inhibitor, is a general term for enzymes that catalyze the hydrolysis of peptide bonds, and this protease is classified into peptidases and proteinases. The former is from outside the amino terminal or carboxyl terminal of the peptide chain.
It is an enzyme that breaks peptide bonds, and the latter is an enzyme that breaks specific bonds inside peptide chains. The latter proteinases are further roughly classified into four types, serine, cysteine, aspartic acid, and metal, depending on the type of active catalytic group, and each has a specific inhibitor. The protease inhibitor in the present invention is characterized by exhibiting inhibitory activity against serine protease among them.
【0011】本発明の肌用外用剤には、上記必須成分以
外に、通常化粧品や医薬品等の皮膚外用剤に用いられる
成分、例えば、水性成分、油性成分、粉末成分、アルコ
ール類、保湿剤、増粘剤、紫外線吸収剤、美白剤、防腐
剤、酸化防止剤、界面活性剤、香料、色剤、各種皮膚栄
養剤等を必要に応じて適宜配合することができる。The external preparation for skin of the present invention contains, in addition to the above-mentioned essential components, components usually used in external preparations for skin such as cosmetics and pharmaceuticals, for example, an aqueous component, an oil component, a powder component, alcohols, a moisturizer, A thickener, an ultraviolet absorber, a whitening agent, a preservative, an antioxidant, a surfactant, a fragrance, a coloring agent, various skin nutritional agents and the like can be appropriately added if necessary.
【0012】その他、エデト酸二ナトリウム、エデト酸
三ナトリウム、クエン酸ナトリウム、ポリリン酸ナトリ
ウム、メタリン酸ナトリウム、グルコン酸等の金属封鎖
剤、カフェイン、タンニン、ベラパミル、甘草抽出物、
グラブリジン、火棘の果実の熱水抽出物、各種生薬、酢
酸トコフェロール、グリチルリチン酸、トラネキサム酸
およびその誘導体またはその塩等の薬剤、ビタミンC、
アスコルビン酸リン酸マグネシウム、アスコルビン酸グ
ルコシド、アルブチン、コウジ酸等の美白剤、グルコー
ス、フルクトース、トレハロース等の糖類なども適宜配
合することができる。[0012] In addition, sequestering agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, caffeine, tannin, verapamil, licorice extract,
Grabridine, hot water extract of fruits of fire thorns, various crude drugs, drugs such as tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or salts thereof, vitamin C,
Whitening agents such as magnesium ascorbyl phosphate, glucoside ascorbate, arbutin and kojic acid, and sugars such as glucose, fructose and trehalose can also be appropriately added.
【0013】[0013]
【実施例】次に実施例によって本発明をさらに詳細に説
明する。なお、本発明はこれにより限定されるものでは
ない。配合量は重量%である。実施例に先立ち、本発明
の植物抽出物の(1)プロテアーゼ阻害作用、(2)肌
荒れ改善作用、(3)老化防止作用、および(4)抗酸
化作用に関する試験方法とその結果について説明する。Next, the present invention will be described in more detail by way of examples. Note that the present invention is not limited to this. The blending amount is% by weight. Prior to Examples, test methods and results of (1) protease inhibitory action, (2) rough skin improving action, (3) anti-aging action, and (4) antioxidant action of the plant extract of the present invention will be described.
【0014】(1)プロテアーゼ阻害作用 代表的な2種類のセリンプロテアーゼとして、プラスミ
ンとトリプシンに対する阻害活性を評価した。(1) Protease Inhibitory Action The inhibitory activity against plasmin and trypsin was evaluated as two typical serine proteases.
【0015】(1-1) 試料の調製 チガヤ根茎の乾燥粉末50gを室温で1週間メタノール
に浸漬し、抽出液を濃縮して、メタノール抽出物1.8
gを得た。この固形物を再びメタノールに溶解し、1%
溶液を作成した。これを用いて以下の実験を行った。(1-1) Preparation of sample 50 g of dried powder of Rhizoma perforatum was immersed in methanol at room temperature for 1 week, and the extract was concentrated to give methanol extract 1.8.
g was obtained. Dissolve this solid in methanol again and add 1%
A solution was made. The following experiment was performed using this.
【0016】(1-2) プラスミン阻害活性の測定 フィブリン平板法にて阻害率%を求めた。すなわちAstr
upら(Arch.Biochem.;40,346,1952)の方法にならいフ
ィブリン平板を作成し、上記のように調製した試料を
0.1%と0.01%にまでエタノールにて希釈して使
用した。結果を表1に示した。(1-2) Measurement of plasmin inhibitory activity The inhibition rate% was determined by the fibrin plate method. Ie Astr
Fibrin plates were prepared according to the method of up et al. (Arch. Biochem .; 40,346, 1952), and the samples prepared as described above were diluted with ethanol to 0.1% and 0.01% and used. The results are shown in Table 1.
【0017】(1-3) トリプシン阻害活性の測定 カゼインを基質としたMuramatuら(J.Biochem.;58,21
4,1965)の方法にならい阻害率を求めた。試料は同じく
0.1%と0.01%にまで希釈したものを使用し、結
果を表1に示した。(1-3) Measurement of trypsin inhibitory activity Muramatu et al. (J. Biochem .; 58, 21) using casein as a substrate.
4, 1965) and the inhibition rate was calculated. Samples were also diluted to 0.1% and 0.01%, and the results are shown in Table 1.
【0018】また、参考例として、すでに肌荒れに対す
る適用が知られている植物であるショウガ(Zingiberac
eae)科のクンイット(Kunyit、学名:Curcuma d
omestica)とヨモギのエタノール抽出物についても上記
と同様の試験を行った。その結果を併せて表1に示す。In addition, as a reference example, ginger (Zingiberac) which is a plant known to be applied to rough skin is already known.
eae) Kunit (scientific name: Curcuma d)
omestica) and wormwood ethanol extract were subjected to the same test as above. Table 1 also shows the results.
【0019】[0019]
【表1】 ──────────────────────────────── 阻害率(%) 試料添加濃度 ─────────────── プラスミン トリプシン ──────────────────────────────── チガヤ 0.1% 76.3 48.9 0.01% 23.6 19.7 クンイット 0.1% 3.0 0 0.01% 0 0 ヨモギ 0.1% 18.6 0 0.01% 5.8 0 ────────────────────────────────[Table 1] ──────────────────────────────── Inhibition rate (%) Sample addition concentration ────── ───────── Plasmin trypsin ──────────────────────────────── Chigaya 0.1% 76.3 48.9 0.01% 23.6 19.7 Khunit 0.1% 3.0 0 0.01% 0 0 Wormwood 0.1% 18.6 0 0.01% 5.8 0 ─────────────────────────────── ──
【0020】(2)肌荒れ改善作用 (2-1) 実使用試験 本発明に係わる外用剤の外皮適用による効果を、肌荒
れ、カミソリ負けに対する改善率、ならびに皮膚刺激性
から評価した。肌荒れで悩む50名の女性パネルの顔面
を用い、表2に示す組成(重量%)のローションのう
ち、左右どちらか一方の頬に試料を、他方の頬に対照を
1日2回、2週間塗布し、その後の肌状態を目視で判定
した。またカミソリ負けする男性パネル30名を対象
に、ひげ剃り直後に表2に示す組成のローションを塗布
し、カミソリ負けに対する効果を判定した。各判定基準
は以下の通りとした。試料としては、本発明品として、
チガヤのメタノール抽出物の濃度を変えたものを2種、
比較品として、すでに肌荒れに対する適用が知られてい
る植物であるショウガ(Zingiberaceae)科のクンイッ
ト(Kunyit、学名:Curcuma domestica)および
ショウガ(Zingiberaceae)科のレムプヤン(Lemp
uyang、学名:Zingiber aromaticum Mal.)のメタ
ノール抽出物を配合したものを用いた。その結果を表3
に示す。(2) Rough skin improving action (2-1) Actual use test The effect of the external preparation of the present invention applied to the outer skin was evaluated from the improvement rate against rough skin and razor loss, and skin irritation. Using the face of a panel of 50 women suffering from rough skin, of the lotions having the composition (% by weight) shown in Table 2, the sample was placed on one of the left and right cheeks, and the other cheek was a control twice a day for 2 weeks. After application, the skin condition after that was visually evaluated. Further, a lotion of 30 men who lost razors was applied with a lotion having the composition shown in Table 2 immediately after shaving, and the effect on razor loss was evaluated. Each criterion was as follows. As a sample, as the product of the present invention,
2 kinds of different concentrations of the methanol extract of Chigaya,
As comparative products, the Kungyit (Curcuma domestica) of the Zingiberaceae family, which is a plant already known to be applied to rough skin, and the Lempyan (Lemp) family of the Zingiberaceae family, are known.
uyang, scientific name: Zingiber aromaticum Mal.) blended with a methanol extract was used. Table 3 shows the results.
Shown in
【0021】 肌荒れに対する改善効果の判定基準 著効:症状の消失したもの。 有効:症状の弱くなったもの。 やや有効:症状がやや弱くなったもの。 無効:症状に変化を認めないもの。Criteria for the improvement effect on rough skin: Remarkable effect: symptom disappeared. Effective: those with reduced symptoms. Somewhat effective: Somewhat weakened symptoms. Ineffective: No change in symptoms.
【0022】 カミソリ負けに対する改善効果の判定
基準 著効:カミソリ負けの消失したもの。 有効:カミソリ負けの弱くなったもの。 やや有効:カミソリ負けがやや弱くなったもの。 無効:カミソリ負けに変化を認めないもの。Criteria for Improvement Effect on Razor Loss Remarkable effect: Razor loss disappeared. Effective: Razor loser weakened. Somewhat effective: Razor losing slightly weakened. Invalid: No change in razor loss.
【0023】 肌荒れ及びカミソリ負けに対する改善
効果 ◎:被験者が著効、有効及びやや有効を示す割合(有効
率)が80%以上。 ○:被験者が著効、有効及びやや有効を示す割合(有効
率)が50%以上〜80%未満。 △:被験者が著効、有効及びやや有効を示す割合(有効
率)が30%以上〜50%未満。 ×:被験者が著効、有効及びやや有効を示す割合(有効
率)が30%未満。Improvement effect on rough skin and razor loss ⊚: 80% or more of the rate (effective rate) at which the test subject is markedly effective, effective and slightly effective. :: The proportion (effective rate) at which the test subject shows a remarkable effect, an effective effect and a somewhat effective effect is 50% or more and less than 80%. Δ: The ratio (effective rate) at which the test subject showed remarkable, effective, and somewhat effective (effective rate) was 30% or more and less than 50%. ×: The ratio (effective rate) at which the subject exhibited significant, effective, and somewhat effective (effective rate) was less than 30%.
【0024】 皮膚刺激性 ◎:肌にヒリヒリ感を認めた被験者の割合が0%。 ○:肌にヒリヒリ感を認めた被験者の割合が5%未満。 △:肌にヒリヒリ感を認めた被験者の割合が10%未
満。 ×:肌にヒリヒリ感を認めた被験者の割合が10%以
上。Skin irritation ⊚: 0% of the subjects recognized tingling on the skin. :: The proportion of subjects who felt tingling on the skin was less than 5%. Δ: The ratio of subjects who felt burning on the skin was less than 10%. ×: The proportion of subjects who felt burning on the skin was 10% or more.
【0025】[0025]
【表2】 ──────────────────────────────── 本発明品 比較品 試 料 ─────── ─────── 2-1 2-2 2-1 2-2 ──────────────────────────────── チガヤ メタノール抽出物 1.0 0.5 − − クンイット メタノール抽出物 − − 1.0 − レムプヤン メタノール抽出物 − − − 1.0 グリセリン 1.0 1.0 1.0 1.0 1,3−ブチレングリコール 4.0 4.0 4.0 4.0 エタノール 7.0 7.0 7.0 7.0 ポリオキシエチレン(20モル) オレイルアルコール 0.5 0.5 0.5 0.5 精製水 残余 残余 残余 残余 ─────────────────────────────────[Table 2] ──────────────────────────────── Inventive product Comparative product Test product ──────── ─────── 2-1 2-2 2-1 2-2 ──────────────────────────────── ─ Tigaya methanol extract 1.0 0.5 − − Khunit methanol extract − − 1.0 − Rempuyan methanol extract − − − 1.0 Glycerin 1.0 1.0 1.0 1.0 1,3-butylene glycol 4.0 4.0 4.0 4.0 Ethanol 7.0 7.0 7.0 7.0 Polyoxyethylene (20 Mol) Oleyl alcohol 0.5 0.5 0.5 0.5 Purified water Residual Residual Residual ──────────────────────────────────
【0026】[0026]
【表3】 ──────────────────────────────── 本発明品 比較品 試 料 ─────── ─────── 2-1 2-2 2-1 2-2 ──────────────────────────────── 肌荒れ改善効果 ◎ ◎ △ △ カミソリ負け改善効果 ◎ ◎ △ △ 皮膚刺激性 ◎ ◎ ○ △ ─────────────────────────────────[Table 3] ──────────────────────────────── Comparative product of the present invention Sample ──────── ─────── 2-1 2-2 2-1 2-2 ──────────────────────────────── ─ Rough skin improvement effect ◎ ◎ △ △ Razor loss improvement effect ◎ ◎ ◎ △ △ Skin irritation ◎ ◎ ○ △ ─────────────────────────── ──────
【0027】表3から明らかなように、チガヤ抽出物を
配合した本発明品の試料は、比較品の試料よりも肌荒
れ、カミソリ負けに対して優れた改善効果を示し、さら
に皮膚刺激性も認められなかった。As is clear from Table 3, the samples of the present invention containing the extract of Tigaya extract showed a better effect on rough skin and razor loss than the samples of the comparative products, and also showed skin irritation. I couldn't do it.
【0028】(2-2) レプリカ法による実使用試験 本発明品2-1,2-2と比較品2-1,2-2のローションを用い
て、人体パネルで肌荒れ改善効果試験を行った。即ち、
女性健常人(顔面)の皮膚表面形態をミリスン樹脂によ
るレプリカ法を用いて肌のレプリカを採り、顕微鏡(1
7倍)にて観察した。皮紋の状態及び角層の剥離状態か
ら、表4に示す基準に基づいて肌荒れ評価が1または2
と判断されたもの(肌荒れパネル)20名を用い、顔面
左右半々に、本発明品2-1,2-2と比較品2-1,2-2のロー
ションを1日2回、2週間塗布した。2週間後、再び上
述のレプリカ法にしたがって肌の状態を観察し、表4の
判定基準にしたがって評価した。その結果を表5に示
す。(2-2) Actual Use Test by Replica Method Using the lotions of the products 2-1 and 2-2 of the present invention and the comparative products 2-1 and 2-2, a skin roughness improving effect test was conducted on a human body panel. . That is,
A replica of the skin surface of a healthy female (face) was taken using a replica method using a millisin resin, and a microscope (1)
7 times). Based on the criteria shown in Table 4, the rough skin evaluation is 1 or 2 based on the state of the skin pattern and the peeling state of the stratum corneum.
Using 20 people judged to be rough (skin rough panel), the lotions of the invention products 2-1 and 2-2 and the comparative products 2-1 and 2-2 were applied to the left and right sides of the face half and twice a day for 2 weeks. did. Two weeks later, the skin condition was observed again according to the above-mentioned replica method, and evaluated according to the criteria shown in Table 4. The results are shown in Table 5.
【0029】[0029]
【表4】 ───────────────────────────────── 評点 評 点 の 基 準 ───────────────────────────────── 1 皮溝、皮丘の消失、広範囲の角層のめくれが認められる。 2 皮溝、皮丘が不鮮明、角層のめくれが認められる。 3 皮溝、皮丘は認められるが、平坦。 4 皮溝、皮丘が鮮明。 5 皮溝、皮丘が鮮明で整っている。 ─────────────────────────────────[Table 4] ───────────────────────────────── Scores Standards of scores ──────── ─────────────────────────── 1 Disappearance of skin crevices, cuticles, and wide-ranging horny layer are observed. 2 Unsmooth skin groove and crust, and horny turn of the stratum corneum. 3 There are pits and ridges, but they are flat. 4 Clear skin grooves and ridges. 5 Crusts and ridges are clear and well organized. ─────────────────────────────────
【0030】[0030]
【表5】 ───────────────────────────────── レプリカ評価 本発明品2-1 本発明品2-2 比較品2-1 比較品2-2 ───────────────────────────────── 1 0 0 1 1 2 0 0 3 2 3 3 4 14 11 4 9 12 2 6 5 8 4 0 0 ─────────────────────────────────[Table 5] ───────────────────────────────── Replica evaluation Inventive product 2-1 Inventive product 2- 2 Comparative product 2-1 Comparative product 2-2 ───────────────────────────────── 1 0 0 1 1 1 2 0 0 3 2 3 3 4 4 14 11 4 9 12 2 6 5 8 8 4 0 0 ──────────────────────────────── ──
【0031】表5から分かるように、本発明品のローシ
ョンは比較品のローションと比較して、顕著な肌荒れ改
善効果が認められた。As can be seen from Table 5, the lotion of the product of the present invention had a remarkable effect of improving rough skin as compared with the lotion of the comparative product.
【0032】(3)老化防止作用 (3-1) ヒト皮膚線維芽細胞のI型コラーゲン産生能に対
する作用の評価 ヒト皮膚線維芽細胞(以下、細胞)を用い、細胞のI型
コラーゲン生合成能に対するチガヤ抽出物の作用を評価
した。チガヤ抽出物の調製は、前記「(1)プロテアー
ゼ阻害作用」の評価の場合と同様に実施した。すなわ
ち、チガヤ根茎の乾燥粉末50gを室温で1週間メタノ
ールに浸漬し、抽出液を濃縮してメタノール抽出物(以
下、チガヤ抽出物)1.8gを得た。(3) Anti-aging action (3-1) Evaluation of action of human skin fibroblasts on type I collagen production ability Using human skin fibroblasts (hereinafter, cells), type I collagen biosynthesis ability of cells The effect of the extract of Spodoptera litura on was evaluated. Preparation of the extract of Cyperus notifolia was carried out in the same manner as in the case of the evaluation of "(1) Protease inhibitory action". That is, 50 g of dry powder of Rhizoma rhizome was immersed in methanol at room temperature for 1 week, and the extract was concentrated to obtain 1.8 g of a methanol extract (hereinafter, Tigaya extract).
【0033】細胞培養用96ウエルプレート(コーニン
グ:25860)に細胞を20000細胞/穴づつ播種した。
10%牛胎児血清(以下、FBSと称する。)を含むR
ITC80−7培地で48時間培養した後、0.5%F
BSを含んだRITC80−7培地(以下、培地と称す
る。)に交換した。その際に、培地中にはジメチルスル
ホキシドに溶解したチガヤ抽出物を添加した。培地中の
ジメチルスルホキシドの濃度は、0.5%となるように
設定し、またチガヤ抽出物濃度は、1ppmとした。チ
ガヤ抽出物を含む培地に交換後、48時間培養した。培
養終了後に、I型コラーゲン生合成能を測定するために
培養上清を、細胞量を計測するために細胞を採取した。
細胞のI型コラーゲン生合成能は、培養上清中に分泌さ
れるI型プロコラーゲンのC端末ペプチド(Procollage
n type IC-peptide:PIPと略す。)量を測定すること
により評価した。具体的には、「Procollagen type IC-
peptide(PIP)測定キット(宝酒造株式会社:MK00
1)」を用いて測定した。細胞量は細胞のDNA量で推
定することとし、DNA量は、Cesar Lsbarcaらの方法
(Analytical Biochemisty,102,344-352,(1980))に準
じてHoechst 33258試薬を用いて測定した。Cells were seeded at 20000 cells / well in a 96-well plate for cell culture (Corning: 25860).
R containing 10% fetal bovine serum (hereinafter referred to as FBS)
After culturing in ITC80-7 medium for 48 hours, 0.5% F
The RITC80-7 medium containing BS (hereinafter referred to as medium) was replaced. At that time, the extract of Cyperus edulis dissolved in dimethylsulfoxide was added to the medium. The concentration of dimethylsulfoxide in the medium was set to be 0.5%, and the concentration of the extract of Tsuchiya was 1 ppm. After the medium was replaced with the medium containing the extract of Tsuchiya extract, the culture was carried out for 48 hours. After the completion of the culture, the culture supernatant was collected to measure the type I collagen biosynthesis ability, and the cells were collected to measure the cell amount.
The type I collagen biosynthesis ability of cells depends on the C-terminal peptide (Procollage) of type I procollagen secreted in the culture supernatant.
n type IC-peptide: Abbreviated as PIP. ) Was evaluated by measuring the amount. Specifically, "Procollagen type IC-
peptide (PIP) measurement kit (Takara Shuzo Co., Ltd .: MK00
1) ”. The amount of cells was estimated by the amount of DNA in the cells, and the amount of DNA was measured using Hoechst 33258 reagent according to the method of Cesar Lsbarca et al. (Analytical Biochemisty, 102, 344-352, (1980)).
【0034】結果を表6に示す。DNA量は若干の増加
傾向を示すものの、有意な変化ではなかったのに対し、
PIP量は有意な増加が観察された。以上のように、チ
ガヤ抽出物は1ppmという極めて低濃度で細胞の増殖
に影響することなくI型コラーゲン生合成能を促進する
効果が認められた。The results are shown in Table 6. Although the amount of DNA showed a slight increasing tendency, it was not a significant change,
A significant increase in the amount of PIP was observed. As described above, it was confirmed that the extract of Porphyra chinensis has an effect of promoting type I collagen biosynthesis without affecting cell proliferation at an extremely low concentration of 1 ppm.
【0035】[0035]
【表6】 ──────────────────────────────── チガヤ抽出物濃度 DNA量(μg/well) PIP量(ng/μgDNA) ──────────────────────────────── 0ppm 0.404±0.038 425.62±66.20 1ppm 0.434±0.062 611.55±72.07 ────────────────────────────────[Table 6] ──────────────────────────────── Tigaya extract concentration DNA amount (μg / well) PIP amount ( ng / μg DNA) ──────────────────────────────── 0ppm 0.404 ± 0.038 425.62 ± 66.20 1ppm 0.434 ± 0.062 611.55 ± 72.07 ────────────────────────────────
【0036】(3-2) 実使用試験 表7に示す処方の実施例3-1および比較例3-1で得られた
クリーム製剤について、それぞれ以下に示す使用試験を
実施した。結果を表8に示す。(3-2) Actual Use Test The following use tests were carried out on the cream formulations obtained in Example 3-1 and Comparative Example 3-1 having the formulations shown in Table 7. Table 8 shows the results.
【0037】[0037]
【表7】 ───────────────────────────────── 実施例3-1 比較例3-1 ───────────────────────────────── (1) セトステアリルアルコール 3.5 3.5 (2) スクワラン 40.0 40.0 (3) ミツロウ 3.0 3.0 (4) 還元ラノリン 4.0 4.0 (5) エチルパラベン 0.3 0.3 (6) ポリオキシエチレン(20)ソルビタン モノパルミチン酸エステル 2.0 2.0 (7) ステアリン酸モノグリセリド 2.0 2.0 (8) チガヤ抽出物 0.5 − (9) N-ステアロイルグルタミン酸ナトリウム 0.5 0.5 (10) 香料 0.03 0.03 (11) 1,3−ブチレングリコール 5.0 5.0 (12) ポリエチレングリコール1500 5.0 5.0 (13) 精製水 残余 残余 ─────────────────────────────────[Table 7] ───────────────────────────────── Example 3-1 Comparative Example 3-1 ─── ────────────────────────────── (1) Cetostearyl alcohol 3.5 3.5 3.5 (2) Squalane 40.0 40 0.0 (3) Beeswax 3.0 3.0 (4) Reduced lanolin 4.0 4.0 (5) Ethylparaben 0.3 0.3 (6) Polyoxyethylene (20) sorbitan monopalmitate 2. 0 2.0 (7) Stearic acid monoglyceride 2.0 2.0 (8) Chigaya extract 0.5- (9) Sodium N-stearoylglutamate 0.5 0.5 (10) Perfume 0.03 0.03 (11) 1,3-Butylene glycol 5.0 5.0 (12) Polyethylene glycol 1500 5.0 5.0 (13) Purified water Residual residue ──────────── ─────────────────────
【0038】 製法 上記表7に示す(1)〜(10)までの原料を加熱溶解する
(油相)。一方、精製水(13)に(11)および(12)を溶解
し、70℃に保った(水相)。そして、この水相に前記
油相を攪拌しながら添加した。次いで、ホモミキサー処
理し、乳化粒子を細かくした後、攪拌しながら後、攪拌
しながら急冷し、所望するクリームを得た。Production Method The raw materials (1) to (10) shown in Table 7 above are melted by heating (oil phase). On the other hand, (11) and (12) were dissolved in purified water (13) and kept at 70 ° C. (aqueous phase). Then, the oil phase was added to the aqueous phase while stirring. Then, the mixture was treated with a homomixer to make the emulsified particles fine, then stirred, and then rapidly cooled with stirring to obtain a desired cream.
【0039】 使用試験 無作為に抽出した年齢25〜57歳の健常な成人女性1
00名を被験者とし、各化粧料を顔面の皮膚に連日1カ
月間使用したのちの、(イ)肌のハリ・タルミに対する
改善効果、および(ロ)シワ・小ジワに対する改善効果
についてそれぞれ調べた。Use test Randomly extracted healthy adult females 25-57 years of age 1
00 subjects were used, and after applying each cosmetic to the facial skin for 1 day every day, the improvement effect on (a) skin firmness / talmi and (b) improvement effect on wrinkles / small wrinkles were examined respectively. .
【0040】(イ)肌のハリに対する改善効果 皮膚の状態を目視にて観察し、以下の評価基準に基づい
て評価した。 (評価基準) A:非常に改善された。 B:改善された。 C:変化がない。 D:少し目につく。 E:目立つようになった。(A) Effect of improving skin firmness The condition of the skin was visually observed and evaluated based on the following evaluation criteria. (Evaluation Criteria) A: Very improved. B: Improved. C: No change. D: A little noticeable. E: It became noticeable.
【0041】(ロ)シワ・小ジワに対する改善効果 皮膚の状態を目視にて観察し、以下の評価基準に基づい
て評価した。 (評価基準) A:きれいに消えた。 B:少し目立たなくなった。 C:変化がない。 D:少し増えた。 E:増えた。(B) Improvement effect on wrinkles and fine wrinkles The condition of the skin was visually observed and evaluated based on the following evaluation criteria. (Evaluation criteria) A: It disappeared neatly. B: It became a little less noticeable. C: No change. D: Increased a little. E: Increased.
【0042】[0042]
【表8】 ─────────────────────────────────── ハリ・タルミに シワ・小ジワに 対する効果(人) 対する効果(人) ───────────── ───────────── A B C D E A B C D E ─────────────────────────────────── 実施例3-1 62 25 13 0 0 37 42 21 0 0 比較例3-1 3 15 76 4 2 0 10 81 8 1 ───────────────────────────────────[Table 8] ─────────────────────────────────── Effect on firmness / talmi, wrinkles, and small wrinkles (Person) Effect on (Person) ───────────── ───────────── A B C C D E A B C C D E ─────── ───────────────────────────── Example 3-1 62 25 13 0 0 37 42 21 0 0 Comparative example 3-1 3 15 76 4 2 0 10 81 8 1 ───────────────────────────────────
【0043】表8に示した結果から明らかなように、実
施例3-1で得られた化粧料を用いた場合には、比較例3-1
で得られた化粧料を用いた場合よりも肌のハリ・タルミ
が著しく改善され、シワや小ジワに対しても極めて有効
であることが明らかとなった。As is clear from the results shown in Table 8, when the cosmetics obtained in Example 3-1 were used, Comparative Example 3-1
It was revealed that the firmness and tarmi of the skin was remarkably improved as compared with the case of using the cosmetic obtained in 1. and it was also extremely effective against wrinkles and fine wrinkles.
【0044】(4)抗酸化作用 (4-1)試料の調製 調製例1(メタノール抽出物) チガヤ根乾燥物1kgに60%メタノールを20kg加
え、室温にて10日間浸漬して抽出し、抽出液を濾過し
た後、メタノールを濃縮してエキスを乾燥残分として5
0g得た。(4) Antioxidant action (4-1) Preparation of sample Preparation Example 1 (methanol extract) To 1 kg of dried cypress root, 20 kg of 60% methanol was added and extracted by immersing at room temperature for 10 days for extraction. After filtering the liquid, the methanol was concentrated to leave the extract as a dry residue.
0 g was obtained.
【0045】 調製例2(クロロホルム抽出物) チガヤ根乾燥物1kgにクロロホルム9kgを加え、5
0℃にて8時間還流して抽出し、抽出液を濾過した後、
クロロホルムを濃縮してエキスを乾燥残分として20g
得た。Preparation Example 2 (Chloroform Extract) 9 kg of chloroform was added to 1 kg of dried dried Cyper root, and 5
After refluxing at 0 ° C. for 8 hours for extraction and filtering the extract,
Chloroform is concentrated and the extract is 20 g as a dry residue.
Obtained.
【0046】 調製例3(メタノール抽出物の精製物) チガヤ根乾燥物1kgにメタノールを10kg加え、還
流煮沸抽出にて8時間還流して抽出し、抽出液を濾過し
た後、濾液を濃縮し、エキス10gを得た。Preparation Example 3 (Purified Methanol Extract) 10 kg of methanol was added to 1 kg of dried dried sardine root, and the mixture was refluxed and extracted for 8 hours by reflux boiling extraction. The extract was filtered, and the filtrate was concentrated. 10 g of extract was obtained.
【0047】(4-2)試験方法および試験結果 1.0mgメチルリノレエート(東京化成工業株式会社
製)/mlアセトン溶液1.0mlと調製例1で調製し
たチガヤ抽出物0.01mg/mlメタノール溶液ある
いは0.1mg/mlメタノール溶液0.1mlをネジ
蓋付き試験官に分注・乾固後、酸化群を50℃で4時間
処理、非酸化群は4℃で保存した。処理後、非水系TB
A試薬(0.12% 2−チオバルビツル酸(和光純薬
株式会社)・0.50%トリエチルアミン(東京化成工
業株式会社)/酢酸)3.0mlを添加し、95℃で1
時間反応させた。反応後直ちに水冷し、532nmの吸
光度を測定し、酸化抑制率を算出した。(4-2) Test method and test results 1.0 mg methyl linoleate (manufactured by Tokyo Kasei Kogyo Co., Ltd.) / Ml 1.0 ml of acetone solution and 0.01 mg / ml of the cypress extract prepared in Preparation Example 1 After 0.1 ml of a methanol solution or 0.1 mg / ml methanol solution was dispensed to a tester with a screw lid and dried, the oxidized group was treated at 50 ° C. for 4 hours and the non-oxidized group was stored at 4 ° C. After treatment, non-aqueous TB
Add 3.0 ml of reagent A (0.12% 2-thiobarbituric acid (Wako Pure Chemical Industries, Ltd.) / 0.50% triethylamine (Tokyo Chemical Industry Co., Ltd.) / Acetic acid), and add 1 at 95 ° C.
Allowed to react for hours. Immediately after the reaction, the mixture was cooled with water, the absorbance at 532 nm was measured, and the oxidation inhibition rate was calculated.
【0048】[0048]
【数1】酸化抑制率(%)=[1−(As50 − As4)/
(Ac50 − Ac4)]×100[Equation 1] Oxidation inhibition rate (%) = [1- (As50-As4) /
(Ac50-Ac4)] × 100
【0049】 Ac50:control 50℃加熱の吸光度。 Ac4 :control 4℃保存の吸光度。 As50:試料 50℃加熱の吸光度。 As4 :試料 4℃保存の吸光度。Ac50: control Absorbance at 50 ° C. heating. Ac4: control Absorbance stored at 4 ° C. As50: Absorbance of sample heated at 50 ° C. As4: Absorbance of sample stored at 4 ° C.
【0050】なお、対照としてチガヤ抽出物に代えてビ
タミンE(DL−α−トコフェロール、東京化成工業株
式会社製)メタノール溶液、BHT(ブチルヒドロキシ
トルエン:和光純薬工業株式会社製)メタノール溶液を
添加したものについても同様に操作した。その結果を表
9に示す。As a control, vitamin E (DL-α-tocopherol, manufactured by Tokyo Kasei Kogyo Co., Ltd.) methanol solution and BHT (butyl hydroxytoluene: Wako Pure Chemical Industries Co., Ltd.) methanol solution were added in place of the cypress extract. The same operation was performed for the ones that were made. The results are shown in Table 9.
【0051】[0051]
【表9】 ──────────────────────────────── 試料No. 抗酸化剤 配合量(mg) 酸化抑制率(%) ──────────────────────────────── 4-1 チガヤ抽出物 0.001 61.9 4-2 チガヤ抽出物 0.01 95.6 ──────────────────────────────── 4-3 ビタミンE 0.001 42.4 4-4 ビタミンE 0.01 82.4 4-5 BHT 0.001 97.3 ────────────────────────────────[Table 9] ──────────────────────────────── Sample No. Antioxidant Compounding amount (mg) Oxidation inhibition rate (%) ──────────────────────────────── 4-1 Chigaya extract 0.001 61.9 4-2 Chigaya extract 0.01 95.6 ──────────────────────────────── 4-3 Vitamin E 0.001 42.4 4-4 Vitamin E 0.01 82.4 4-5 BHT 0.001 97.3 ─────────────────────────────────
【0052】表9に示す如く、チガヤ抽出物はビタミン
Eより優れた抗酸化作用を示し、さらにチガヤ抽出物の
濃度を上げればBHTと同等の著しい抗酸化作用を示
す。As shown in Table 9, Tigaya extract shows an antioxidant effect superior to that of vitamin E. Further, when the concentration of Tigaya extract is increased, it shows a remarkable antioxidant action equivalent to BHT.
【0053】実施例1 クリーム (処方) ステアリン酸 5.0 重量% ステアリルアルコール 4.0 イソプロピルミリステート 18.0 グリセリンモノステアリン酸エステル 3.0 プロピレングリコール 10.0 チガヤメタノール抽出物 0.01 苛性カリ 0.2 亜硫酸水素ナトリウム 0.01 防腐剤 適量 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールとチガヤ
メタノール抽出物と苛性カリを加え溶解し、加熱して7
0℃に保つ(水相)。他の成分を混合し加熱融解して7
0℃に保つ(油相)。水相に油相を徐々に加え、全部加
え終わってからしばらくその温度に保ち反応を起こさせ
る。その後、ホモミキサーで均一に乳化し、よくかきま
ぜながら30℃まで冷却する。Example 1 Cream (formulation) Stearic acid 5.0% by weight Stearyl alcohol 4.0 Isopropyl myristate 18.0 Glycerin monostearate 3.0 Propylene glycol 10.0 Chigaya methanol extract 0.01 Caustic potash 0 .2 Sodium bisulfite 0.01 Preservative Suitable amount Perfume Suitable amount Ion-exchanged water Residual (production method) Propylene glycol, Tigaya methanol extract and caustic potash were added to ion-exchanged water and dissolved, and heated to 7
Keep at 0 ° C. (aqueous phase). Mix other ingredients, heat and melt.
Keep at 0 ° C. (oil phase). The oil phase is gradually added to the water phase, and after the addition is completed, the temperature is maintained for a while to cause a reaction. Then, it is uniformly emulsified with a homomixer and cooled to 30 ° C. with thorough stirring.
【0054】実施例2 クリーム (処方) ステアリン酸 2.0 重量% ステアリルアルコール 7.0 水添ラノリン 2.0 スクワラン 5.0 2−オクチルドデシルアルコール 6.0 ポリオキシエチレン(25モル)セチルアルコールエー
テル 3.0 グリセリンモノステアリン酸エステル 2.0 プロピレングリコール 5.0 チガヤエタノール抽出物 0.05 トラネキサム酸 0.2 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え、
加熱して70℃に保つ(水相)。他の成分を混合し加熱
融解して70℃に保つ(油相)。水相に油相を加え予備
乳化を行い、ホモミキサーで均一に乳化した後、よくか
きまぜながら30℃まで冷却する。Example 2 Cream (formulation) Stearic acid 2.0% by weight Stearyl alcohol 7.0 Hydrogenated lanolin 2.0 Squalane 5.0 2-Octyldodecyl alcohol 6.0 Polyoxyethylene (25 mol) cetyl alcohol ether 3.0 Glycerin monostearate 2.0 Propylene glycol 5.0 Chigaya ethanol extract 0.05 Tranexamic acid 0.2 Ethylparaben 0.3 Fragrance suitable amount Ion-exchanged water Residual (production method) Add propylene glycol to ion-exchanged water ,
Heat and maintain at 70 ° C. (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is added to the aqueous phase to carry out preliminary emulsification, and the mixture is uniformly emulsified with a homomixer and then cooled to 30 ° C. with thorough stirring.
【0055】実施例3 クリーム (処方) 固形パラフィン 5.0 重量% ミツロウ 10.0 ワセリン 15.0 流動パラフィン 41.0 グリセリンモノステアリン酸エステル 2.0 ポリオキシエチレン(20モル)ソルビタンモノラウリ
ン酸エステル 2.0 石けん粉末 0.1 チガヤアセトン抽出物 0.05 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水に石けん粉末を加え、加熱して7
0℃に保つ(水相)。他の成分を混合し加熱融解して7
0℃に保つ(油相)。水相に油相をかきまぜながら徐々
に加え反応を行う。反応終了後、ホモミキサーで均一に
乳化し、乳化後よくかきまぜながら30℃まで冷却す
る。Example 3 Cream (Formulation) Solid paraffin 5.0% by weight Beeswax 10.0 Vaseline 15.0 Liquid paraffin 41.0 Glycerin monostearate 2.0 Polyoxyethylene (20 mol) sorbitan monolaurate 2 0.0 Soap powder 0.1 Chigaya acetone extract 0.05 Sodium hydrogen sulfite 0.03 Ethylparaben 0.3 Perfume proper amount Ion-exchanged water Residual (production method) Add soap powder to ion-exchanged water and heat to 7
Keep at 0 ° C. (aqueous phase). Mix other ingredients, heat and melt.
Keep at 0 ° C. (oil phase). The oil phase is gradually added to the aqueous phase while stirring to carry out the reaction. After the reaction is completed, the mixture is uniformly emulsified with a homomixer, and after emulsification, the mixture is cooled to 30 ° C. with thorough stirring.
【0056】 実施例4 乳液 (処方) ステアリン酸 2.5 重量% セチルアルコール 1.5 ワセリン 5.0 流動パラフィン 10.0 ポリオキシエチレン(10モル)モノオレイン酸エステル 2.0 ポリエチレングリコール1500 3.0 トリエタノールアミン 1.0 カルボキシビニルポリマー 0.05 (商品名:カーボポール941,B.F.Goodrich Chemical company) チガヤ酢酸エチルエステル抽出物 0.01 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)少量のイオン交換水にカルボキシビニルポリマ
ーを溶解する(A相)。残りのイオン交換水にポリエチ
レングリコール1500とトリエタノールアミンを加
え、加熱溶解して70℃に保つ(水相)。他の成分を混
合し加熱融解して70℃に保つ(油相)。水相に油相を
加え予備乳化を行い、A相を加えホモミキサーで均一に
乳化し、乳化後よくかきまぜながら30℃まで冷却す
る。Example 4 Emulsion (formulation) Stearic acid 2.5% by weight Cetyl alcohol 1.5 Vaseline 5.0 Liquid paraffin 10.0 Polyoxyethylene (10 mol) monooleate 2.0 Polyethylene glycol 1500 3. 0 Triethanolamine 1.0 Carboxyvinyl polymer 0.05 (trade name: Carbopol 941, BFGoodrich Chemical company) Ethyl acetate extract of Tigaya acetate 0.01 Sodium hydrogen sulfite 0.01 Ethylparaben 0.3 Perfume Suitable amount Ion-exchanged water Residual (manufacturing method) The carboxyvinyl polymer is dissolved in a small amount of ion-exchanged water (phase A). Polyethylene glycol 1500 and triethanolamine are added to the remaining ion-exchanged water, dissolved by heating, and kept at 70 ° C. (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is added to the water phase, pre-emulsification is performed, phase A is added, and the mixture is uniformly emulsified with a homomixer. After the emulsification, the mixture is cooled to 30 ° C. while stirring well.
【0057】実施例5 乳液 (処方) マイクロクリスタリンワックス 1.0 重量% ミツロウ 2.0 ラノリン 20.0 流動パラフィン 10.0 スクワラン 5.0 ソルビタンセスキオレイン酸エステル 4.0 ポリオキシエチレン(20モル)ソルビタンモノオレイ
ン酸エステル 1.0 プロピレングリコール 7.0 チガヤブタノール抽出物 5.0 トラネキサム酸 1.0 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え、
加熱して70℃に保つ(水相)。他の成分を混合し、加
熱融解して70℃に保つ(油相)。油相をかきまぜなが
らこれに水相を徐々に加え、ホモミキサーで均一に乳化
する。乳化後、よくかきまぜながら30℃まで冷却す
る。Example 5 Emulsion (Formulation) Microcrystalline wax 1.0% by weight Beeswax 2.0 Lanolin 20.0 Liquid paraffin 10.0 Squalane 5.0 Sorbitan sesquioleate 4.0 Polyoxyethylene (20 mol) Sorbitan monooleate 1.0 Propylene glycol 7.0 Ciguay butanol extract 5.0 Tranexamic acid 1.0 Sodium hydrogen sulfite 0.01 Ethylparaben 0.3 Perfume proper amount Ion-exchanged water Residual (production method) Propylene to ion-exchanged water Add glycol,
Heat and maintain at 70 ° C. (aqueous phase). The other components are mixed, heated and melted and kept at 70 ° C. (oil phase). While stirring the oil phase, the aqueous phase is gradually added thereto, and the mixture is uniformly emulsified with a homomixer. After emulsification, cool to 30 ° C. while stirring well.
【0058】 実施例6 ゼリー (処方) 95%エチルアルコール 10.0 重量% ジプロピレングリコール 15.0 ポリオキシエチレン(50モル)オレイルアルコールエーテル 2.0 カルボキシビニルポリマー 0.05 (商品名:カーボポール940,B.F.Goodrich Chemical company) 苛性ソーダ 0.15 L−アルギニン 0.1 チガヤ50%メタノール水溶液抽出物 0.01 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にカーボポール940を均一に溶
解し、一方、95%エタノールにチガヤ50%メタノー
ル水溶液抽出物、ポリオキシエチレン(50モル)オレ
イルアルコールエーテルを溶解し、水相に添加する。次
いで、その他の成分を加えたのち、苛性ソーダ、L−ア
ルギニンで中和させ増粘する。Example 6 Jelly (formulation) 95% ethyl alcohol 10.0 wt% dipropylene glycol 15.0 polyoxyethylene (50 mol) oleyl alcohol ether 2.0 carboxyvinyl polymer 0.05 (trade name: Carbopol 940, BFGoodrich Chemical company) Caustic soda 0.15 L-arginine 0.1 Chigaya 50% methanol aqueous solution extract 0.01 Sodium hydrogen sulfite 0.01 Ethylparaben 0.3 Perfume proper amount Ion-exchanged water Residue (production method) For ion-exchanged water Carbopol 940 is uniformly dissolved, while 50% methanol extract of Tigaya 50% aqueous solution and polyoxyethylene (50 mol) oleyl alcohol ether are dissolved in 95% ethanol and added to the aqueous phase. Next, after adding other components, the mixture is neutralized with caustic soda and L-arginine to increase the viscosity.
【0059】実施例7 ゼリー (処方) (A相) エチルアルコール(95%) 10.0 重量% ポリオキシエチレン(20モル)オクチルドデカノール
1.0 パントテニールエチルエーテル 0.1 チガヤメタノール抽出物 1.5 メチルパラベン 0.15 (B相) 水酸化カリウム 0.1 (C相) グリセリン 5.0 ジプロピレングリコール 10.0 亜硫酸水素ナトリウム 0.03 カルボキシビニルポリマー 0.2(商品
名:カーボポール940,B.F.Goodrich Chemical compan
y) 精製水 残余 (製法)A相、C相をそれぞれ均一に溶解し、C相にA
相を加えて可溶化する。次いでB相を加えたのち充填を
行う。Example 7 Jelly (formulation) (Phase A) Ethyl alcohol (95%) 10.0% by weight Polyoxyethylene (20 mol) Octyldodecanol 1.0 Pantothenyl ethyl ether 0.1 Chigaya methanol extract 1 .5 Methylparaben 0.15 (Phase B) Potassium hydroxide 0.1 (Phase C) Glycerin 5.0 Dipropylene glycol 10.0 Sodium hydrogen sulfite 0.03 Carboxyvinyl polymer 0.2 (trade name: Carbopol 940, BFGoodrich Chemical compan
y) Purified water Residual (production method) Phases A and C are uniformly dissolved,
Add phases and solubilize. Next, after adding the phase B, filling is performed.
【0060】実施例8 パック (処方) (A相) ジプロピレングリコール 5.0 重量% ポリオキシエチレン(60モル)硬化ヒマシ油 5.0 (B相) チガヤアセトン抽出物 0.01 オリーブ油 5.0 酢酸トコフェロール 0.2 エチルパラベン 0.2 香料 0.2 (C相) 亜硫酸水素ナトリウム 0.03 ポリビニルアルコール 13.0 (ケン化度90、重合度2,000) エタノール 7.0 精製水 残余 (製法)A相、B相、C相をそれぞれ均一に溶解し、A
相にB相を加えて可溶化する。次いでこれをC相に加え
たのち充填を行う。Example 8 Pack (Formulation) (Phase A) Dipropylene glycol 5.0% by weight Polyoxyethylene (60 mol) hydrogenated castor oil 5.0 (Phase B) Tigaya acetone extract 0.01 Olive oil 5.0 Tocopherol acetate 0.2 Ethylparaben 0.2 Perfume 0.2 (Phase C) Sodium hydrogen sulfite 0.03 Polyvinyl alcohol 13.0 (Saponification degree 90, degree of polymerization 2,000) Ethanol 7.0 Purified water Residual (manufacturing method ) A phase, B phase, and C phase are uniformly dissolved,
Add phase B to phase and solubilize. Next, this is added to the C phase and then filled.
【0061】実施例9 固形ファンデーション (処方) タルク 43.1 重量% カオリン 15.0 セリサイト 10.0 亜鉛華 7.0 二酸化チタン 3.8 黄色酸化鉄 2.9 黒色酸化鉄 0.2 スクワラン 8.0 イソステアリン酸 4.0 モノオレイン酸POEソルビタン 3.0 オクタン酸イソセチル 2.0 チガヤエタノール抽出物 1.0 防腐剤 適量 香料 適量 (製法)タルク〜黒色酸化鉄の粉末成分をブレンダーで
十分混合し、これにスクワラン〜オクタン酸イソセチル
の油性成分、チガヤエタノール抽出物、防腐剤、香料を
加え良く混練した後、容器に充填、成型する。Example 9 Solid Foundation (Formulation) Talc 43.1% by weight Kaolin 15.0 Sericite 10.0 Zinc white 7.0 Titanium dioxide 3.8 Yellow iron oxide 2.9 Black iron oxide 0.2 Squalane 8 0.0 isostearic acid 4.0 POE sorbitan monooleate 3.0 isocetyl octanoate 2.0 chigaya ethanol extract 1.0 preservative appropriate amount perfume appropriate amount (manufacturing process) Talc to black iron oxide powder components are thoroughly mixed with a blender. Then, an oily component of squalane to isocetyl octoate, an extract of Chigaya ethanol, a preservative and a fragrance are added, and the mixture is well kneaded and then filled into a container and molded.
【0062】実施例10 乳化型ファンデーション (処方) (粉体部) 二酸化チタン 10.3 重量% セリサイト 5.4 カオリン 3.0 黄色酸化鉄 0.8 ベンガラ 0.3 黒色酸化鉄 0.2 (油相) デカメチルシクロペンタシロキサン 11.5 流動パラフィン 4.5 ポリオキシエチレン変性ジメチルポリシロキサン 4.
0 (水相) 精製水 50.0 1,3−ブチレングリコール 4.5 チガヤメタノール抽出物 1.5 ソルビタンセスキオレイン酸エステル 3.0 防腐剤 適量 香料 適量 (製法)水相を加熱攪拌後、十分に混合粉砕した粉体部
を添加してホモミキサー処理する。更に加熱混合した油
相を加えてホモミキサー処理した後、攪拌しながら香料
を添加して室温まで冷却する。Example 10 Emulsified Foundation (Prescription) (Powder Part) Titanium Dioxide 10.3% by Weight Sericite 5.4 Kaolin 3.0 Yellow Iron Oxide 0.8 Bengala 0.3 Black Iron Oxide 0.2 ( Oil phase) Decamethylcyclopentasiloxane 11.5 Liquid paraffin 4.5 Polyoxyethylene-modified dimethylpolysiloxane 4.
0 (Aqueous phase) Purified water 50.0 1,3-Butylene glycol 4.5 Chigaya methanol extract 1.5 Sorbitan sesquioleate 3.0 Preservative proper amount Perfume proper amount (Production method) After heating and stirring the aqueous phase, it is sufficient. Then, the powder portion which has been mixed and pulverized is added to the mixture and homomixed. Further, the oil phase mixed by heating is added, and the mixture is treated with a homomixer. Then, a fragrance is added with stirring, and the mixture is cooled to room temperature.
【0063】[0063]
【発明の効果】以上説明したように、本発明の肌用外用
剤は、優れた老化防止作用を有する。すなわち、太陽光
(紫外線)曝露に伴い、真皮における主要な細胞である
線維芽細胞の増殖活性やコラーゲン等の合成機能が低下
して生ずる皮膚への傷害を抑制し、さらに受けた損傷を
回復させることにより、弾力があり、シワやたるみがな
くハリがある皮膚が維持増進され得る。また、それと共
に、肌荒れ改善作用にも優れ、種々の皮膚疾患、肌荒
れ、荒れ性等の改善・予防に優れた効果を有するもので
ある。さらに、抗酸化作用にも優れているので、化粧品
に配合することにより、皮膚脂質成分の酸化防止や皮膚
の酸化傷害等にも有効性を発揮し、皮膚を保護すること
ができる。As described above, the external preparation for skin of the present invention has an excellent antiaging effect. That is, with the exposure to sunlight (ultraviolet rays), the proliferation activity of fibroblasts, which are the main cells in the dermis, and the synthetic function of collagen, etc. are reduced, and the damage to the skin caused by the suppression is suppressed and the damage received is restored. This may help to maintain and improve elastic, firm skin without wrinkles or sagging. At the same time, it also has an excellent effect of improving rough skin, and has an excellent effect of improving and preventing various skin diseases, rough skin, rough skin, and the like. Furthermore, since it also has an excellent antioxidant effect, it can be effectively protected against oxidation of skin lipid components, oxidative damage to the skin, and the like by being incorporated into cosmetics to protect the skin.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 和田 元次 神奈川県横浜市港北区新羽町1050番地 株 式会社資生堂第一リサーチセンター内 (72)発明者 合津 陽子 神奈川県横浜市港北区新羽町1050番地 株 式会社資生堂第一リサーチセンター内 ─────────────────────────────────────────────────── ─── Continuation of front page (72) Inventor Motoji Wada 1050 Shinba-cho, Kohoku-ku, Yokohama-shi, Kanagawa Inside Shiseido Daiichi Research Center Co., Ltd. Banchi Co., Ltd. Shiseido Daiichi Research Center
Claims (5)
の抽出物を配合することを特徴とする肌用外用剤。1. Chigaya (scientific name: Imperata cylindrica)
An external preparation for skin characterized by containing the extract of.
の抽出物を有効成分とすることを特徴とする老化防止
剤。2. Chigaya (scientific name: Imperata cylindrica)
An anti-aging agent, characterized by comprising an extract of the above as an active ingredient.
の抽出物を有効成分とすることを特徴とする肌荒れ改善
剤。3. Chigaya (scientific name: Imperata cylindrica)
An agent for improving skin roughness, which comprises the extract of as an active ingredient.
の抽出物を有効成分とすることを特徴とする抗酸化剤。4. Chigaya (scientific name: Imperata cylindrica)
An antioxidant, characterized in that the extract is an active ingredient.
0.00001〜20.0重量%である請求項1〜4の
いずれかに記載の剤。5. The blended amount of Chigaya extract in terms of dry matter,
The agent according to any one of claims 1 to 4, which is 0.00001 to 20.0% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8148699A JPH09309841A (en) | 1996-05-20 | 1996-05-20 | Preparation for external use for skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8148699A JPH09309841A (en) | 1996-05-20 | 1996-05-20 | Preparation for external use for skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09309841A true JPH09309841A (en) | 1997-12-02 |
Family
ID=15458628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8148699A Withdrawn JPH09309841A (en) | 1996-05-20 | 1996-05-20 | Preparation for external use for skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH09309841A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805161A1 (en) * | 2000-02-23 | 2001-08-24 | Sederma Sa | COMPOSITIONS FOR COSMETIC OR DERMOPHARMACEUTICAL USE CONTAINING AN EXTRACT OF IMPERATA, IN PARTICULAR IMPERATA CYLINDRICA L. |
| JP2010195729A (en) * | 2009-02-26 | 2010-09-09 | Kao Corp | Skin color-changing agent, hair color-changing agent and pheomelanin production-promoting agent |
| KR101303295B1 (en) * | 2011-07-22 | 2013-09-03 | 이상록 | The cosmetic composition for promoting cell growth and recovery of distrupted skin containing the extracts of fermented Mistletoe, fermented Imperata cylindrica and fermented soybean |
| CN111184822A (en) * | 2018-11-14 | 2020-05-22 | 大江生医股份有限公司 | Use of Rhizoma Imperatae fermented product to enhance gene expression, promote collagen and elastin proliferation, and enhance antioxidant capacity |
| CN115350196A (en) * | 2022-10-17 | 2022-11-18 | 山东科金生物发展有限公司 | Biological preparation for reducing skin aging and improving skin injury repair |
| KR102692059B1 (en) * | 2023-12-28 | 2024-08-06 | (주)엔비바이오컴퍼니 | A cosmetic composition for anti-oxidation, anti-inflammation, protecting effect of skin cell from fine dust, and skin soothing comprising nano liposome comprising artemisia capillaris extract, angelica japonica extract, and imperata cylindrica extract |
-
1996
- 1996-05-20 JP JP8148699A patent/JPH09309841A/en not_active Withdrawn
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805161A1 (en) * | 2000-02-23 | 2001-08-24 | Sederma Sa | COMPOSITIONS FOR COSMETIC OR DERMOPHARMACEUTICAL USE CONTAINING AN EXTRACT OF IMPERATA, IN PARTICULAR IMPERATA CYLINDRICA L. |
| WO2001062218A1 (en) * | 2000-02-23 | 2001-08-30 | Sederma | Composition for cosmetic or dermopharmaceutical use containing an imperata extract, in particular an imperata cylindrica l extract |
| JP2010195729A (en) * | 2009-02-26 | 2010-09-09 | Kao Corp | Skin color-changing agent, hair color-changing agent and pheomelanin production-promoting agent |
| KR101303295B1 (en) * | 2011-07-22 | 2013-09-03 | 이상록 | The cosmetic composition for promoting cell growth and recovery of distrupted skin containing the extracts of fermented Mistletoe, fermented Imperata cylindrica and fermented soybean |
| CN111184822A (en) * | 2018-11-14 | 2020-05-22 | 大江生医股份有限公司 | Use of Rhizoma Imperatae fermented product to enhance gene expression, promote collagen and elastin proliferation, and enhance antioxidant capacity |
| CN111184822B (en) * | 2018-11-14 | 2026-04-17 | 大江生医股份有限公司 | Uses of Imperata cylindrica root ferment for promoting collagen production and its manufacturing method |
| CN115350196A (en) * | 2022-10-17 | 2022-11-18 | 山东科金生物发展有限公司 | Biological preparation for reducing skin aging and improving skin injury repair |
| CN115350196B (en) * | 2022-10-17 | 2023-02-03 | 山东科金生物发展有限公司 | Biological preparation for reducing skin aging and improving skin injury repair |
| KR102692059B1 (en) * | 2023-12-28 | 2024-08-06 | (주)엔비바이오컴퍼니 | A cosmetic composition for anti-oxidation, anti-inflammation, protecting effect of skin cell from fine dust, and skin soothing comprising nano liposome comprising artemisia capillaris extract, angelica japonica extract, and imperata cylindrica extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001192317A (en) | Matrix metalloproteinases inhibitor | |
| JPH11315008A (en) | Antiaging agent | |
| JPH1017461A (en) | Preparation for external use for improving skin roughness | |
| JPH1179971A (en) | Anti-aging agent | |
| JPH11246338A (en) | Anti-aging agent | |
| JP3410870B2 (en) | External preparation for skin | |
| KR19990022333A (en) | Skin external preparation for improving and preventing skin roughness | |
| JPH0987136A (en) | Dermal preparation for external use | |
| JPH09309841A (en) | Preparation for external use for skin | |
| JPH11246387A (en) | Antiaging agent | |
| JPH1017460A (en) | Antiageing agent | |
| JPH11246337A (en) | Anti-aging agent | |
| JPH0925213A (en) | Skin preparation for external use | |
| JPH0925212A (en) | Skin preparation for external use | |
| JPH1179970A (en) | Collagenase inhibitor | |
| JP2000256122A (en) | Matrix metalloproteinases inhibitor | |
| JPH1129468A (en) | Protease inhibitor | |
| JPH11246385A (en) | Antiaging agent | |
| JPH10182414A (en) | Anti-aging agent | |
| JPH11246386A (en) | Elastase inhibitor | |
| JPH1129467A (en) | Protease inhibitor | |
| JPH0920643A (en) | External preparation for improving chapped skin | |
| JPH11240842A (en) | Protease inhibitor | |
| JPH11335230A (en) | Skin lotion | |
| JP2000136146A (en) | Protease inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20030805 |